| Literature DB >> 35311017 |
Tianyi Wang1,2,3, Kaiqi Long1,2,3, Yang Zhou1,2,3, Xiaoding Jiang4, Jinzhao Liu3, John H C Fong5, Alan S L Wong5,6, Wai-Lung Ng4, Weiping Wang1,2,3.
Abstract
As an important regulator of cell metabolism, proliferation, and survival, mTOR (mammalian target of rapamycin) signaling provides both a potential target for cancer treatment and a research tool for investigation of cell metabolism. One inhibitor for both mTORC1 and mTORC2 pathways, OSI-027, exhibited robust anticancer efficacy but induced side effects. Herein, we designed a photoactivatable OSI-027 prodrug, which allowed the release of OSI-027 after light irradiation to inhibit the mTOR signaling pathway, triggering autophagy and leading to cell death. This photoactivatable prodrug can provide novel strategies for mTOR-targeting cancer therapy and act as a new tool for investigating mTOR signaling and its related biological processes.Entities:
Year: 2022 PMID: 35311017 PMCID: PMC8922298 DOI: 10.1021/acsptsci.1c00230
Source DB: PubMed Journal: ACS Pharmacol Transl Sci ISSN: 2575-9108